Cargando…
Multiple systemic treatment options in a patient with malignant tenosynovial giant cell tumour
Tenosynovial giant cell tumour (TGCT) is a group of rare soft tissues neoplasia affecting synovial joints, bursae and tendon sheaths and is classified as localized type or diffuse type. The diffuse type (TGCT-D), also known as ‘pigmented villonodular (teno)synovitis’ is characterized by local aggres...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6903349/ https://www.ncbi.nlm.nih.gov/pubmed/31567307 http://dx.doi.org/10.1097/CAD.0000000000000844 |
_version_ | 1783477836548407296 |
---|---|
author | Rebuzzi, Sara Elena Grassi, Massimiliano Catalano, Fabio Buscaglia, Michele Bertulli, Rossella Satragno, Camilla Belgioia, Liliana Comandini, Danila |
author_facet | Rebuzzi, Sara Elena Grassi, Massimiliano Catalano, Fabio Buscaglia, Michele Bertulli, Rossella Satragno, Camilla Belgioia, Liliana Comandini, Danila |
author_sort | Rebuzzi, Sara Elena |
collection | PubMed |
description | Tenosynovial giant cell tumour (TGCT) is a group of rare soft tissues neoplasia affecting synovial joints, bursae and tendon sheaths and is classified as localized type or diffuse type. The diffuse type (TGCT-D), also known as ‘pigmented villonodular (teno)synovitis’ is characterized by local aggressivity, with invasion and destruction of adjacent soft-tissue structures, and high local recurrence rate. Radical surgery remains the standard therapy while adjuvant radiotherapy may help to control local spread. Malignant TGCT is characterized by high rate of local recurrences and distant metastasis. Few cases of malignant TGCT and very few evidences on systemic therapies are described in the literature, so, to date, no systemic treatment is approved for this rare disease. We report the case of a malignant TGCT patient treated with many different systemic therapies, including chemotherapy and tyrosine-kinase inhibitors, and performed a review of the literature on the systemic treatment options of this rare tumour. |
format | Online Article Text |
id | pubmed-6903349 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-69033492020-01-22 Multiple systemic treatment options in a patient with malignant tenosynovial giant cell tumour Rebuzzi, Sara Elena Grassi, Massimiliano Catalano, Fabio Buscaglia, Michele Bertulli, Rossella Satragno, Camilla Belgioia, Liliana Comandini, Danila Anticancer Drugs Case Reports Tenosynovial giant cell tumour (TGCT) is a group of rare soft tissues neoplasia affecting synovial joints, bursae and tendon sheaths and is classified as localized type or diffuse type. The diffuse type (TGCT-D), also known as ‘pigmented villonodular (teno)synovitis’ is characterized by local aggressivity, with invasion and destruction of adjacent soft-tissue structures, and high local recurrence rate. Radical surgery remains the standard therapy while adjuvant radiotherapy may help to control local spread. Malignant TGCT is characterized by high rate of local recurrences and distant metastasis. Few cases of malignant TGCT and very few evidences on systemic therapies are described in the literature, so, to date, no systemic treatment is approved for this rare disease. We report the case of a malignant TGCT patient treated with many different systemic therapies, including chemotherapy and tyrosine-kinase inhibitors, and performed a review of the literature on the systemic treatment options of this rare tumour. Lippincott Williams & Wilkins 2020-01 2019-12-06 /pmc/articles/PMC6903349/ /pubmed/31567307 http://dx.doi.org/10.1097/CAD.0000000000000844 Text en Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (http://creativecommons.org/licenses/by-nc-nd/4.0/) (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
spellingShingle | Case Reports Rebuzzi, Sara Elena Grassi, Massimiliano Catalano, Fabio Buscaglia, Michele Bertulli, Rossella Satragno, Camilla Belgioia, Liliana Comandini, Danila Multiple systemic treatment options in a patient with malignant tenosynovial giant cell tumour |
title | Multiple systemic treatment options in a patient with malignant tenosynovial giant cell tumour |
title_full | Multiple systemic treatment options in a patient with malignant tenosynovial giant cell tumour |
title_fullStr | Multiple systemic treatment options in a patient with malignant tenosynovial giant cell tumour |
title_full_unstemmed | Multiple systemic treatment options in a patient with malignant tenosynovial giant cell tumour |
title_short | Multiple systemic treatment options in a patient with malignant tenosynovial giant cell tumour |
title_sort | multiple systemic treatment options in a patient with malignant tenosynovial giant cell tumour |
topic | Case Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6903349/ https://www.ncbi.nlm.nih.gov/pubmed/31567307 http://dx.doi.org/10.1097/CAD.0000000000000844 |
work_keys_str_mv | AT rebuzzisaraelena multiplesystemictreatmentoptionsinapatientwithmalignanttenosynovialgiantcelltumour AT grassimassimiliano multiplesystemictreatmentoptionsinapatientwithmalignanttenosynovialgiantcelltumour AT catalanofabio multiplesystemictreatmentoptionsinapatientwithmalignanttenosynovialgiantcelltumour AT buscagliamichele multiplesystemictreatmentoptionsinapatientwithmalignanttenosynovialgiantcelltumour AT bertullirossella multiplesystemictreatmentoptionsinapatientwithmalignanttenosynovialgiantcelltumour AT satragnocamilla multiplesystemictreatmentoptionsinapatientwithmalignanttenosynovialgiantcelltumour AT belgioialiliana multiplesystemictreatmentoptionsinapatientwithmalignanttenosynovialgiantcelltumour AT comandinidanila multiplesystemictreatmentoptionsinapatientwithmalignanttenosynovialgiantcelltumour |